Novelix Pharmaceuticals Ltd vs Vaishali Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Novelix Pharmaceuticals Ltd is ₹ 55.01 as of 06 May 15:30 . The P/E Ratio of Novelix Pharmaceuticals Ltd is 0 as of March 2021 .The P/E Ratio of Vaishali Pharma Ltd is 0 as of March 2021 . The Market Cap of Novelix Pharmaceuticals Ltd is ₹ 5.48 crore as of March 2021 .The Market Cap of Vaishali Pharma Ltd is ₹ 0 crore as of March 2021 . The Revenue of Novelix Pharmaceuticals Ltd is ₹ 0 crore as of Jun '25 .The Revenue of Vaishali Pharma Ltd is ₹ 24.59 crore as of Jun '25 . The EBITDA of Novelix Pharmaceuticals Ltd is ₹ 0 crore as of Jun '25 .The EBITDA of Vaishali Pharma Ltd is ₹ 2.21 crore as of Jun '25 . The Net Profit of Novelix Pharmaceuticals Ltd is ₹ 0 crore as of Jun '25 .The Net Profit of Vaishali Pharma Ltd is ₹ 1.28 crore as of Jun '25 . The Dividend Payout of Novelix Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Vaishali Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Novelix Pharmaceuticals Ltd

Trimurthi Limited was formerly incorporated on December 13, 1994 with the name Trimurthi Securities Ltd. The name of the Company thereafter got changed from Trimurthi Securities Ltd to Trimurthi Drugs & Pharmaceuticals Ltd. In September 2006, as per the Scheme of Arrangement, the erstwhile Trimurthi Drugs & Pharmaceuticals Ltd amalgamated with the Company.
Also, the name of the Company was changed to Trimurthi Drugs & Pharmaceuticals Ltd and again to Trimurthi Limited in May, 2016. Initially, the company was engaged in finance and investments in securities.
They ceased their operations due to the high volatility in the markets and voluntarily got de-registered as Non-Banking financial company.
Thereafter, the company explored the possibilities of entering into pharmaceutical and drug industry by way of diversification.

About Vaishali Pharma Ltd

Vaishali Pharma Limited was originally incorporated as a Private Limited Company with the name 'Vaishali Pharma Private Limited' on 25th, April 2008.
On July 01, 2008 the Company acquired the business of proprietorship concerns of its Promoter Mr. Atul Vasani viz.
M/s.
Vaishali Pharmachem through Business Assignment agreement.
Consequently, the business of said Proprietorship Firm merged into Vaishali Pharma Private Limited.

FAQs for the comparison of Novelix Pharmaceuticals Ltd and Vaishali Pharma Ltd

Which company has a larger market capitalization, Novelix Pharmaceuticals Ltd or Vaishali Pharma Ltd?

Market cap of Novelix Pharmaceuticals Ltd is 58 Cr while Market cap of Vaishali Pharma Ltd is 98 Cr

What are the key factors driving the stock performance of Novelix Pharmaceuticals Ltd and Vaishali Pharma Ltd?

The stock performance of Novelix Pharmaceuticals Ltd and Vaishali Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Novelix Pharmaceuticals Ltd and Vaishali Pharma Ltd?

As of May 6, 2026, the Novelix Pharmaceuticals Ltd stock price is INR ₹40.5. On the other hand, Vaishali Pharma Ltd stock price is INR ₹7.58.

How do dividend payouts of Novelix Pharmaceuticals Ltd and Vaishali Pharma Ltd compare?

To compare the dividend payouts of Novelix Pharmaceuticals Ltd and Vaishali Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.